Descripción del proyecto
Las gotas para los ojos pueden interrumpir la respuesta de autoinmunidad en enfermedades oculares graves
Las enfermedades inflamatorias oculares, también denominadas uveítis, son un grupo variado de enfermedades inflamatorias de origen autoinmune o infeccioso que pueden producir ceguera. A pesar del progreso realizado mediante el uso de terapias con esteroides, no existe un tratamiento efectivo y el uso a largo plazo de esteroides puede provocar complicaciones graves. TRS ha desarrollado una molécula patentada inspirada en la naturaleza que interrumpe el mecanismo autoinmune que provoca las enfermedades. De este modo, tiene el potencial de tratar la progresión de las enfermedades y no solo mejorar los síntomas. La tecnología estará disponible en forma de gotas e inyecciones para tratar todas las partes del ojo en función de cada enfermedad concreta. La financiación europea está respaldando los ensayos clínicos, cuyos resultados ayudarán a asegurar la financiación para la comercialización.
Objetivo
Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences.
Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness.
Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases.
Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market.
In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineophthalmologyglaucoma
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicineimmunology
- social sciencessociologygovernancetaxation
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
3093765 Zichron Yaakov
Israel
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.